| 靶标 | A4, ABPP, AD1, AICD-50, AICD-57, AICD-59, AID(50), AID(57), AID(59), APP, APPI, Abeta40, Abeta42, Alpha-CTF, Alpha-secretase C-terminal fragment, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid intracellular domain 50, Amyloid intracellular domain 57, Amyloid intracellular domain 59, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Amyloid-beta precursor protein, Amyloid-beta protein 40, Amyloid-beta protein 42, Beta-APP40, Beta-APP42, Beta-CTF, Beta-secretase C-terminal fragment, C31, C80, C83, C99, CVAP, Cerebral vascular amyloid peptide, Gamma-CTF(50), Gamma-CTF(57), Gamma-CTF(59), Gamma-secretase C-terminal fragment 50, Gamma-secretase C-terminal fragment 57, Gamma-secretase C-terminal fragment 59, N-APP, P3(40), P3(42), PN-II, PreA4, Protease nexin-II, S-APP-alpha, S-APP-beta, Soluble APP-alpha, Soluble APP-beta |
|---|
| 背景 | Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi). 1. Baumkötter, F. et al. (2014) The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 11159-72. PMID: 251229122. Satpute-Krishnan, P. et al. (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 16532-7. PMID: 170627543. Seamster, PE. et al. (2012) Physical biology 9, 055005. PMID: 23011729 |
|---|
